Trium Capital discloses 11% stake in Mural Oncology
PositiveFinancial Markets

Trium Capital has announced that it holds an 11% stake in Mural Oncology, marking a significant investment in the biotech sector. This move highlights Trium's confidence in Mural's innovative approaches to cancer treatment, which could lead to advancements in patient care and potentially lucrative returns for investors. Such investments are crucial as they support the development of groundbreaking therapies that can change lives.
— Curated by the World Pulse Now AI Editorial System